Attached files
| file | filename |
|---|---|
| EX-10.52 - EMPLOYMENT AGREEMENT WITH DOUGLAS PLASSCHE - ELITE PHARMACEUTICALS INC /NV/ | f10k2021ex10-52_elitepharma.htm |
| 10-K - ANNUAL REPORT - ELITE PHARMACEUTICALS INC /NV/ | f10k2021_elitepharma.htm |
| EX-32.1 - CERTIFICATION - ELITE PHARMACEUTICALS INC /NV/ | f10k2021ex32-1_elitepharma.htm |
| EX-31.2 - CERTIFICATION - ELITE PHARMACEUTICALS INC /NV/ | f10k2021ex31-2_elitepharma.htm |
| EX-31.1 - CERTIFICATION - ELITE PHARMACEUTICALS INC /NV/ | f10k2021ex31-1_elitepharma.htm |
| EX-23.1 - CONSENT OF BUCHBINDER TUNICK & COMPANY LLP, INDEPENDENT REGISTERED PUBLIC ACCOUN - ELITE PHARMACEUTICALS INC /NV/ | f10k2021ex23-1_elitepharma.htm |
| EX-10.54 - JULY 29, 2019 AMENDMENT TO THE LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT BETWEE - ELITE PHARMACEUTICALS INC /NV/ | f10k2021ex10-54_elitepharma.htm |
| EX-10.53 - JUNE 21, 2019 RETENTION AGREEMENT WITH DOUGLAS PLASSCHE - ELITE PHARMACEUTICALS INC /NV/ | f10k2021ex10-53_elitepharma.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Elite Pharmaceuticals, Inc. (the “Registrant”) on Form 10-K for the year ended March 31, 2021 filed with the Securities and Exchange Commission (the “Report”), I, Marc Bregman, Chief Financial Officer and Treasurer of the Registrant, certify, pursuant to 18 U.S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
Information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
| Date: June 14, 2021 | /s/ Marc Bregman |
|
Marc Bregman Chief Financial Officer, Treasurer and Secretary (Principal Accounting and Financial Officer) |
This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
A signed original of this written statement required by Section 906 has been provided to Elite Pharmaceuticals, Inc. and will be retained by Elite Pharmaceuticals Inc. and furnished to the Securities and Exchange Commission or its staff upon request.